Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.
TABLE OF CONTENTS
4 Product Profiles
4 Xolair : Asthma
LIST OF FIGURES
11 Figure 1: Asthma – current and future market dynamics analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Xolair in asthma
13 Figure 2: Datamonitor Healthcare’s assessment summary of key marketed and pipeline drugs for asthma
16 Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES 4Table 1: Xolair drug profile
6 Table 2: Xolair pivotal trial data in asthma
10 Table 3: Xolair late-phase trial data in asthma
17 Table 4: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.